[AACR] A randomized, multicenter phase III study of once-per-cycle administration of efbemalenograstim alfa (F-627), a novel long-acting dimeric rhG-CSF, for prophylaxis of chemotherapy-induced neutropenia in patients with breast cancer Closed
|
Reward30points
|
post
reply
points
50
30
Novel WRN Helicase Inhibitors Selectively Target Microsatellite Unstable Cancer Cells.
30
The Cancer Spectrum Theory
30
Abstract B137: Selective inhibition of the active state of KRASG12V with the non-covalent, tri-complex inhibitor RM-048
30
Abstract 3391: Dual inhibition of RAS and the IGF2/IGF1R pathways: a potential targeting strategy for RAS-mutated embryonal rhabdomyosarcoma
